We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

81 hedge funds and large institutions have $164M invested in Protagonist Therapeutics in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

13.19% more ownership

Funds ownership: 72.06% → 85.25% (+13%)

7% more funds holding

Funds holding: 76 → 81 (+5)

28% less capital invested

Capital invested by funds: $228M → $164M (-$64M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
81
Holders Change
+5
Holders Change %
+6.58%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
18
Increased
34
Reduced
15
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$16.9M
2
SFM
Sphera Funds Management
Israel
+$6.26M
3
BlackRock
BlackRock
New York
+$4.75M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$2.48M
5
O
OrbiMed
New York
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
VMI
VHCP Management III
New York
-$9.85M
2
ACP
Acuta Capital Partners
California
-$5.03M
3
VMI
VHCP Management II
New York
-$3.92M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.95M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$28.8M +$1.38M +138,955 +4%
RI
2
RTW Investments
New York
$17.3M +$16.9M +1,697,705 +223%
JJIJ
3
Johnson & Johnson Innovation - JJDC
New Jersey
$17.3M +$24.3M +2,449,183 New
BlackRock
4
BlackRock
New York
$11M +$4.75M +478,755 +44%
FCM
5
Farallon Capital Management
California
$10.6M – – –
BBA
6
Baker Bros. Advisors
New York
$8.28M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.98M +$539K +54,243 +6%
Millennium Management
8
Millennium Management
New York
$5.97M +$90.4K +9,102 +1%
BI
9
BVF Inc
California
$4.81M – – –
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$4.73M -$601K -60,554 -8%
SFM
11
Sphera Funds Management
Israel
$4.44M +$6.26M +630,000 New
Renaissance Technologies
12
Renaissance Technologies
New York
$4.36M +$626K +63,024 +11%
NHAS
13
Novo Holdings A/S
Denmark
$3.38M – – –
Citadel Advisors
14
Citadel Advisors
Florida
$3.24M +$425K +42,838 +10%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$3.04M +$997K +100,348 +30%
State Street
16
State Street
Massachusetts
$2.38M +$230K +23,127 +7%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$2.25M +$1.66M +166,800 +110%
GTC
18
Ghost Tree Capital
New York
$1.94M +$248K +25,000 +10%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.91M +$93.6K +9,425 +4%
JP Morgan Chase
20
JP Morgan Chase
New York
$1.82M -$235K -23,692 -8%
Canada Pension Plan Investment Board
21
Canada Pension Plan Investment Board
Ontario, Canada
$1.76M +$2.48M +250,000 New
Northern Trust
22
Northern Trust
Illinois
$1.73M -$9.27K -933 -0.4%
Two Sigma Investments
23
Two Sigma Investments
New York
$1.44M +$1.53M +154,463 +313%
N
24
Nuveen
North Carolina
$1.37M +$436K +43,906 +29%
O
25
OrbiMed
New York
$1.35M +$1.9M +191,209 New
1
2 3 4

PTGX Hedge Fund Activity: Q4 2019 in Review

81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2019, worth a combined $164M — down 28% from $228M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PTGX positions and 13 closed out — a net gain of 5 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was VHCP Management III, cutting an estimated $9.85M.

  • 81 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2019, up from 76 in Q3 2019.
  • Funds reported $164M of Protagonist Therapeutics stock for Q4 2019, down 28% quarter-over-quarter.
  • 18 funds opened new Protagonist Therapeutics positions in Q4 2019 and 13 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2019 was RTW Investments, an estimated $16.9M added.
  • The largest Protagonist Therapeutics seller in Q4 2019 was VHCP Management III, an estimated $9.85M sold.

Based on aggregated 13F filings for Q4 2019.